Japer Therapeutics Warrants
JSPRW
6 hedge funds and large institutions have $236K invested in Japer Therapeutics Warrants in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
96% more capital invested
Capital invested by funds: $121K → $236K (+$116K)
0.5% more ownership
Funds ownership: 2.17% → 2.67% (+0.5%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
25% less funds holding
Funds holding: 8 → 6 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$81.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
Ionic Capital Management
New York
|
-$20.9K |
| 2 |
Walleye Capital
New York
|
-$450 |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAC
1
Cowen and Company
New York
| $148K | +$81.3K | +979,440 | +113% |
|
|
2
Walleye Capital
New York
| $55.6K | -$450 | -5,422 | -0.8% |
|
|
TCM
3
Tenor Capital Management
New York
| $20K | – | – | – |
|
|
CL
4
CSS LLC
Chicago,
Illinois
| $6.56K | – | – | – |
|
|
ZA
5
Zazove Associates
Incline Village,
Nevada
| $5K | – | – | – |
|
6
Walleye Trading
New York
| $1.13K | – | – | – |
|
|
ICM
7
Ionic Capital Management
New York
| – | -$20.9K | -417,132 | Closed |
|
|
8
UBS Group
Zurich,
Switzerland
| – | -$2 | -37 | Closed |
|
JSPRW Hedge Fund Activity: Q4 2023 in Review
6 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Japer Therapeutics Warrants (JSPRW) for Q4 2023, worth a combined $236K — up 96% from $121K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of JSPRW and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was Cowen and Company, adding an estimated $81.3K. The largest seller was Ionic Capital Management, exiting entirely with an estimated $20.9K sold.
- 6 institutional investors held Japer Therapeutics Warrants (JSPRW) as of Q4 2023, down from 8 in Q3 2023.
- Funds reported $236K of Japer Therapeutics Warrants stock for Q4 2023, up 96% quarter-over-quarter.
- 0 funds opened new Japer Therapeutics Warrants positions in Q4 2023 and 2 closed out, a net change of -2 holders.
- The largest Japer Therapeutics Warrants buyer in Q4 2023 was Cowen and Company, an estimated $81.3K added.
- The largest Japer Therapeutics Warrants seller in Q4 2023 was Ionic Capital Management, an estimated $20.9K sold.
Based on aggregated 13F filings for Q4 2023.